Hemopoietic progenitor cell mobilization and harvest following an intensive chemotherapy debulking in indolent lymphoma patients

Stem Cells

Volumn 17, Issue 1, 1999, Pages 55-61

  Tarella, Corrado ^a,b   Zallio, Francesco ^a   Caracciolo, Daniele ^a   Cherasco, Cristina ^a   Bondesan, Paola ^a   Gavarotti, Paolo ^a   Corradini, Paolo ^a   Tassi, Valter ^b   Pileri, Alessandro ^a  

^a Divisione Universitaria di Ematologia   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Chemotherapy; Indolent lymphoma; Mobilization; PBPC; Tumor contamination

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; COLONY FORMING UNIT GM; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKAPHERESIS; LYMPHOMA; MALE;

EID: 0032944432     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.170055     Document Type: Article

References (35)

1. Coiffier B. Towards a cure in indolent lymphoproliferative diseases? Eur J Cancer 1995;31a:2135-2137.
2. Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before ABMT for B-cell lymphoma. N Engl J Med 1991;325:1525-1531.
3. Rohatiner A, Johnson P, Price C et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994;12:1177-1184.
4. Provan D, Bartlett-Pandite L, Zwicky C et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996;88:2228-2235.
5. Bastion Y, Brice P, Haioun C et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995;86:3257-3262.
6. Haas R, Moos M, Mhole R et al. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1996;17:149-155.
7. Tarella C, Gavarotti P, Caracciolo D et al. Haematological support of high-dose sequential chemotherapy: clinical evidence for reduction of toxicity and high response rate in poor risk lymphomas. Ann Oncol 1995;6(suppl 4):3-8.
8. Tarella C, Boccadoro M, Omedè P et al. Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma. Bone Marrow Transplant 1993;11:271-277.
9. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBPCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994;87:825-831.
10. Hardingham JE, Kotasek D, Sage RE et al. Molecular detection of residual lymphoma cells in peripheral blood stem cell harvests and following autologous transplantation. Bone Marrow Transplant 1993;11:15-20.
11. Haas R, Mohle R, Fruhauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994;83:3787-3794.
12. Dreger P, Kloss M, Petersen B et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995;86:3970-3978.
13. Watts MJ, Sullivan AM, Jamieson E et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997;15:535-546.
14. Tarella C, Castellino C, Cherasco C et al. Peripheral blood progenitor cell mobilization in patients with primary refractory lymphoma or at first relapse: comparison with patients at diagnosis and impact on clinical outcome. Br J Haematol 1997;99:41-46.
15. Tarella C, Caracciolo D, Gavarotti P et al. Circulating progenitors following high-dose sequential (HDS) chemotherapy with G-CSF: short intervals between drug courses severely impair progenitor mobilization. Bone Marrow Transplant 1995;16:223-228.
16. Akard LP, Wiemann M, Thompson JM et al. Impaired stem cell collection by consecutive courses of high-dose mobilizing chemotherapy using cyclophosphamide, etoposide, and G-CSF. J Hematother 1996;5:271-277.
17. Gianni AM, Bonadonna G. High-dose chemoradiotherapy for sensitive tumors: is sequential better than concurrent drug delivery? Eur J Cancer Clin Oncol 1989;25:1027-1030.
18. Gianni AM, Siena S, Bregni M et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haematopoietic stem cells for autotransplantation. Lancet 1989;2:580-585.
19. Corradini P, Astolfi M, Cherasco C et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphoma treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 1997;89:724-731.
20. Weinstein HJ, Cassady JR, Levey R. Long-term results of the APO protocol (vincristine, doxorubicin (Adriamycin), and prednisone) for treatment of mediastinal lymphoblastic lymphoma. J Clin Oncol 1983;1:537-541.
21. Velasquez WS, Cabanillas F, Salvador P et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethasone (DHAP). Blood 1988;71:117-122.
22. Mulder POM, Sleijfer DT, Willemse PHB. High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. Cancer Res 1989;49:4654-4658.
23. Siena S, Bregni M, Brando B et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991;77:400-409.
24. Tarella C, Benedetti G, Caracciolo D et al. Both early and committed haematopoietic progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF. Br J Haematol 1995;91:535-543.
25. Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997;336:1290-1297.
26. Moss TJ, Ross AA. The risk of tumor cell contamination in peripheral blood stem cell collections. J Hematother 1992;1:225-232.
27. Ross AA, Cooper BW, Lazarus HM et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993;82:2605-2610.
28. Brugger W, Bross KJ, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994;83:636-640.
29. Gianni AM, Siena S, Bregni M et al. Efficacy, toxicity and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol 1997;15:2312-2321.
30. Shea TC, Mason JR, Breslin M et al. Reinfusion and serial measurements of carboplatin-mobilized peripheral-blood progenitor cells in patients receiving multiple cycles of high-dose chemotherapy. J Clin Oncol 1994;12:1012-1020.
31. Gribben JG, Neuberg D, Freedman AS et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993;81:3449-3557.
32. + bone marrow progenitor cells in patients with non-Hodgkin's lymphoma. Blood 1995;85:1647-1654.
33. + cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. Blood 1994;84:1421-1426.
34. Mapara MY, Korner IJ, Hildebrandt M et al. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction. Blood 1997;89:337-344.
35. Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457-2466.